MARKET

CRMD

CRMD

Cormedix
NASDAQ
11.22
-0.49
-4.18%
After Hours: 11.28 +0.06 +0.53% 17:57 07/11 EDT
OPEN
11.70
PREV CLOSE
11.71
HIGH
11.73
LOW
11.19
VOLUME
1.34M
TURNOVER
--
52 WEEK HIGH
17.43
52 WEEK LOW
3.610
MARKET CAP
833.82M
P/E (TTM)
49.80
1D
5D
1M
3M
1Y
5Y
1D
CorMedix Inc. Advances Pediatric Dialysis Safety with New Clinical Study
TipRanks · 5h ago
CorMedix’s DEFENCATH® Study: A Potential Game-Changer in Infection Prevention
TipRanks · 1d ago
RBC Capital Keeps Their Buy Rating on Cormedix (CRMD)
TipRanks · 4d ago
Weekly Report: what happened at CRMD last week (0630-0704)?
Weekly Report · 4d ago
CorMedix Completes $82.2 Million Stock Offering
TipRanks · 06/30 20:59
CorMedix Analyst Says Investors Could Be Further Rewarded
Benzinga · 06/30 18:24
CorMedix Seems Significantly Undervalued
Seeking Alpha · 06/30 18:14
This CorMedix Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday
Benzinga · 06/30 17:17
More
About CRMD
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.

Webull offers CorMedix Inc stock information, including NASDAQ: CRMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRMD stock methods without spending real money on the virtual paper trading platform.